ESC 365 - Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk: insights from the ETNA-AF-China 1-year follow-up

ESC Professional Premium Access

Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk: insights from the ETNA-AF-China 1-year follow-up

Session: Oral anticoagulant therapy for atrial fibrillation in clinical practice

Topic: Oral Anticoagulation

Speaker: Doctor J. Du (Shanghai, CN)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Juan Du

Shanghai (China)

0 follower

7 more presentations in this session

Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation

Speaker: Doctor T. Chao (Taipei, TW)

Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study

Speaker: Associate Professor I. Diemberger (Bologna, IT)

Impact of resumption of Oral AntiCoagulation therapy (OAC) after GastroIntestinal Bleeding (GIB) on clinical outcomes in patients with Non-Valvular Atrial Fibrillation (NVAF)

Speaker: Doctor W. Sun (Shatin, HK)

The efficacy and safety of NOAC in very elderly atrial fibrillation patients; data from the Korean national health insurance cohort registry

Speaker: Doctor S. Choi (Incheon, KR)

Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Global registry

Speaker: Professor G. Boriani (Modena, IT)

Access the full session

Oral anticoagulant therapy for atrial fibrillation in clinical practice

Speakers: Doctor J. Du, Doctor T. Chao, Associate Professor I. Diemberger, Doctor W. Sun, Doctor S. Choi...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources